Home›Oncology› Lower lenvatinib starting doses show no clear response benefit in advanced endometrial cancer
Lower lenvatinib starting doses show no clear response benefit in advanced endometrial cancerLower Lenvatinib Doses Show No Extra Benefit for Endometrial Cancer
Frontiers in MedicinePublished October 16, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Interpret lower lenvatinib starting doses cautiously; observational data show no clear response benefit.
This meta-analysis pooled 10 independent observational cohorts comprising 1,000 adults with previously treated advanced or recurrent endometrial cancer to compare starting lenvatinib below 20 mg with a 20 mg starting dose. The authors examined objective response as the primary outcome, along with disease control, subsequent dose reduction, interruption, permanent discontinuation, grade 3 or higher adverse events, progression-free survival, hospitalization, and treatment persistence.
For objective response, the pooled risk ratio was 0.97 (95% CI, 0.70-1.34), and for disease control it was 0.96 (95% CI, 0.83-1.11), indicating no significant difference between starting doses. The risk ratio for subsequent lenvatinib dose reduction was 0.66 (95% CI, 0.34-1.27), a direction favoring lower starting doses but with a confidence interval that includes no effect.
The authors rated the overall risk of bias as serious and certainty as very low for all pooled comparisons. Estimates for interruption, permanent discontinuation, grade 3 or higher adverse events, and progression-free survival were imprecise, and hospitalization and treatment persistence could not be pooled. Adverse events were not poolable, and funding or conflicts of interest were not reported.
The observational design means comparative evidence does not establish that starting lenvatinib below 20 mg preserves antitumor effectiveness or improves tolerability relative to a 20 mg starting dose. These findings should be interpreted as preliminary and hypothesis-generating rather than practice-changing.
How this fits prior evidence
This meta-analysis addresses a practical dosing question in endometrial cancer, a disease area where prior coverage has focused on single-cell omics identifying TREM2+ macrophages and LAG-3/TIM-3 as actionable targets. Unlike prior coverage of pembrolizumab, regorafenib, and cabozantinib in advanced hepatocellular carcinoma, which reported overall survival benefits, this analysis found no significant difference in objective response or disease control with lower lenvatinib starting doses. The very low certainty and observational design contrast with the more definitive survival data highlighted in prior immunotherapy coverage, underscoring the need for randomized evidence before changing starting-dose practice.
Researchers looked at data from 1,000 adults with advanced or recurrent endometrial cancer. They compared patients who started on a lower dose of lenvatinib (under 20 mg) against those who started on a 20 mg dose. The goal was to see if a lower starting dose helped patients tolerate the medicine better or improved their results.
The analysis showed no significant difference in how the cancer responded to the treatment or how well the disease was controlled between the two groups. While the lower dose group had a lower risk of needing a dose reduction later on, the overall effectiveness of the drug remained the same regardless of the starting dose.
It is important to note that this study was based on observational data and had a very low level of certainty. Because the data was not from a randomized trial, it cannot prove that one dose is better than the other. Patients should talk to their doctors to decide on the best dosing plan for their specific needs.
What this means for you:
Lower starting doses of lenvatinib do not appear to improve treatment results for advanced endometrial cancer.
Common questions
Does starting with a lower dose of lenvatinib help with side effects?
The study found that patients starting with a dose below 20 mg had a lower risk of needing a dose reduction later. However, the data had very low certainty, and the study did not provide enough information to confirm if lower doses improved overall tolerability or safety for those with advanced endometrial cancer.
Is a lower dose of lenvatinib more effective for cancer control?
The analysis of 1,000 patients showed no significant difference in disease control or objective response between those who started on a lower dose and those who started on 20 mg. The results suggest that starting with a lower dose does not improve the effectiveness of the treatment.
How reliable is the evidence for lenvatinib dosing?
The evidence for these findings is considered to have very low certainty. Because the data came from observational studies rather than a randomized trial, it is not enough to change standard medical practice. Patients should consult their doctors regarding specific treatment plans.
BackgroundLenvatinib plus pembrolizumab is an established treatment for patients with previously treated advanced or recurrent endometrial cancer. In routine practice, clinicians may select a lenvatinib starting dose below 20 mg for patients expected to have limited tolerance, but the comparative effectiveness and tolerability of that strategy remain uncertain.MethodsWe searched PubMed/MEDLINE, Web of Science Core Collection, and Cochrane CENTRAL from inception to 11 July 2026, with source-specific updates completed on 13–14 July 2026. Comparative observational studies of adults receiving lenvatinib plus pembrolizumab were eligible. The primary estimand compared starting doses below 20 mg with 20 mg; a 10-mg threshold contrast and first-8-week relative dose intensity were kept separate. Binary outcomes were summarized as risk ratios (RRs) and time-to-event outcomes as hazard ratios (HRs). Risk of bias was assessed with ROBINS-I, missing-evidence bias with ROB-ME, and certainty with GRADE.ResultsTen studies representing 10 independent cohorts and 1,000 patients were included. Five cohorts (703 patients in total) informed the primary starting-dose comparison, with outcome-specific analysis denominators. For starting doses below 20 mg versus 20 mg, the pooled RR was 0.97 for objective response (95% confidence interval [CI], 0.70–1.34; I²=11.9%) and 0.96 for disease control (95% CI, 0.83–1.11; I²=0%). The RR for subsequent lenvatinib dose reduction was 0.66 (95% CI, 0.34–1.27; I²=27.4%). Estimates for interruption, permanent discontinuation, grade 3 or higher adverse events, and progression-free survival were imprecise; hospitalization and treatment persistence were not poolable. Every evaluated result had serious overall risk of bias, and certainty was very low for all pooled comparisons.ConclusionComparative observational evidence does not establish that starting lenvatinib below 20 mg preserves antitumor effectiveness or improves tolerability relative to a 20 mg starting dose. Prospective, confounder-aware comparative studies are needed before a reduced starting-dose strategy can be recommended broadly.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261458417.
